Delbos Florent, Bertrand Gérald, Croisille Laure, Ansart-Pirenne Hélène, Bierling Philippe, Kaplan Cécile
Laboratoire HLA/ILP, Etablissement Français du Sang, Créteil.
Platelet Immunology, Institut National de la Transfusion Sanguine, Paris, France.
Transfusion. 2016 Jan;56(1):59-66; quiz 58. doi: 10.1111/trf.13274. Epub 2015 Sep 7.
In Caucasians, fetal/neonatal alloimmune thrombocytopenia (FNAIT) is most frequently caused by maternal alloimmunization against the human platelet antigen HPA-1a. The most serious complication of severe FNAIT is intracranial hemorrhage (ICH). ICH mainly occurs in utero; therefore, there is a need to identify noninvasive predictive factors of ICH to facilitate early identification of this condition and to determine response to maternal therapy.
We studied gynecologic and immunogenetic variables of severe cases of anti-HPA-1a FNAIT within three groups: Group I, FNAIT without ICH; Group II, FNAIT with ICH; and Group III, suspected FNAIT cases without detectable maternal anti-HPA-1a alloantibodies.
ICH was associated with a poor outcome because it led to death in 59% of cases. Multigravida (two or more pregnancies) was overrepresented in Group II, consistent with the high concentrations of maternal HPA-1a alloantibody and the frequent detection of a strong newborn-specific HLA class I antibody response at delivery. The proportion of HLA-DRB401:01P (01:01 or 01:03) women was similar in Groups I and II, but this allele was overrepresented in Group III, in which FNAIT was less severe than in the other two groups. Finally, antenatal intravenous immunoglobulin therapy tended to be more effective in HLA-DRB301:01(+)/HLA-DRB401:01P(+) women than for HLA-DRB301:01(+)/HLA-DRB4*01:01P(-) women.
The number of gestations is a predictive factor of ICH in anti-HPA-1a-alloimmunized women. Maternal immunogenetic variables should be investigated in the context of maternal immunization and may predict response to maternal therapy in subsequent pregnancies.
在白种人中,胎儿/新生儿同种免疫性血小板减少症(FNAIT)最常见的原因是母亲针对人类血小板抗原HPA-1a的同种免疫。严重FNAIT最严重的并发症是颅内出血(ICH)。ICH主要发生在子宫内;因此,需要识别ICH的非侵入性预测因素,以便于早期识别这种情况并确定对母亲治疗的反应。
我们研究了三组严重抗HPA-1a FNAIT病例的妇科和免疫遗传学变量:第一组,无ICH的FNAIT;第二组,有ICH的FNAIT;第三组,疑似FNAIT病例但未检测到母亲抗HPA-1a同种抗体。
ICH与不良结局相关,因为它导致59%的病例死亡。多产妇(两次或更多次怀孕)在第二组中占比过高,这与母亲HPA-1a同种抗体的高浓度以及分娩时频繁检测到强烈的新生儿特异性HLA I类抗体反应一致。HLA-DRB401:01P(01:01或01:03)女性在第一组和第二组中的比例相似,但该等位基因在第三组中占比过高,其中FNAIT比其他两组轻。最后,产前静脉注射免疫球蛋白治疗在HLA-DRB301:01(+)/HLA-DRB401:01P(+)女性中往往比在HLA-DRB301:01(+)/HLA-DRB4*01:01P(-)女性中更有效。
妊娠次数是抗HPA-1a同种免疫女性ICH的预测因素。应在母亲免疫的背景下研究母亲的免疫遗传学变量,并且这些变量可能预测后续妊娠中对母亲治疗的反应。